Corcept Therapeutics Misses Q1 Revenue and EPS, Shares Slide 4.5% After Hours

Earnings Summary

Corcept posted Q1 revenue of $164.9 million, a modest 4.9% year‑over‑year increase but an 11.3% shortfall against the $185.8 million consensus estimate. GAAP earnings came in at a loss of $0.30 per share, missing the $0.11 per‑share estimate by $0.19. Operating expenses jumped to $214.5 million from $153.8 million a year earlier, reflecting heavy investment in the launch of Lifyorli™ (relacorilant) for platinum‑resistant ovarian cancer and expanded Cushing’s‑syndrome initiatives.

Guidance and Outlook

Despite the miss, management raised full‑year 2026 revenue guidance to $950‑$1,050 million, up from the prior $850‑$950 million range. CEO Joseph K. Belanoff emphasized that this quarter marks “the last quarter for which our financial results will reflect the sales of just one medication,” noting vigorous uptake of Lifyorli after its inclusion in NCCN guidelines. The company also reiterated its expectation to return to profitability in Q2 2026.

Conference Call Highlights

- FDA approval: Lifyorli received FDA approval for platinum‑resistant ovarian cancer three months ahead of its PDUFA date, a rare regulatory win that the company highlighted as a catalyst for near‑term sales.

- Commercial rollout: The drug was added to NCCN guidelines in April, and the company reported “all‑time highs” in patient starts for both Korlym and its authorized generic.

- Pipeline progress: Phase 2 BELLA trial results are expected by year‑end, with additional oncology studies (platinum‑sensitive ovarian, endometrial, cervical, pancreatic) slated for 2027. The SYNERGY study with nivolumab and the MONARCH MASH trial also target releases next year.

- Cushing’s‑syndrome focus: Relacorilant’s Phase 3 GRACE trial results were published in The Lancet Diabetes & Endocrinology in February, supporting the company’s push for an NDA.

Market Reaction & Analyst Commentary

The after‑hours sell‑off to $44.41 reflects investors’ disappointment with the revenue miss and higher expense base, even as guidance was upgraded. Canaccord Genuity responded positively, lifting its price target from $100 to $110 and assigning a “Buy” rating, citing the strong commercial momentum of Lifyorli and the upside of the expanded guidance. Conversely, a StockStory recap highlighted the revenue miss as the primary driver of the price decline, noting that the market remains cautious until the company demonstrates sustained profitability.

Why the Stock Fell Despite Guidance Upgrade

1. Revenue miss outweighs guidance lift: The $21 million revenue shortfall was larger than the incremental upside implied by the new guidance range, prompting a short‑term re‑pricing.

2. Higher cash burn: Operating expenses rose 39% year‑over‑year, raising concerns about cash runway despite a solid $515.4 million cash balance.

3. Execution risk on launch: Investors are waiting for concrete sales data on Lifyorli; early uptake is encouraging, but the drug still represents a single‑product revenue stream for the remainder of the year.

4. Profitability timeline: Management’s promise of Q2 profitability is viewed as a near‑term milestone, but analysts remain split on the certainty of that target.

Outlook

If Lifyorli’s commercial traction continues and the upcoming BELLA and SYNERGY trial readouts are positive, Corcept could validate its higher‑end guidance and justify the elevated price target. However, the company must contain operating costs and demonstrate cash‑flow positivity in Q2 to calm short‑term skeptics.

---

All figures are from Corcept’s Q1 2026 8‑K filing and consensus estimates compiled by MarketBeat and Zacks. Stock price reflects after‑hours trading at 5:55 PM ET.